Summary
The regulation of similar bio-therapeutic products varies widely among the different Latin American countries. While some of them are yet to introduce their own regulation, others — like Brazil and Mexico — have opened ways to cheaper, complex and safe biological treatment for patients. However, many things need improving and a lot of experience is still necessary to develop a mature LATAM Biosimilars Market.
Biosimilars Latam – Mexico 2018 is a unique and effective meeting point to share the information and experience Latin America’s Pharmaceutical Industry needs to develop a dynamic and thriving biosimilars market.
Join us in Mexico and trigger a quantum leap in Latin American Healthcare!
Who will
you meet?
More than:
Participants
Companies
HCPs
Patients
Academy
Investors
Institutions
Associations
Service Providers
Government Agencies
Industry Executives from Latam
From these areas:
- Biosimilars
- Biobetters
- Biotechnology
- Biotherapeutics
- Analytical science
- Regulatory compliance
- Quality Control
- Clinical immunology
- Scientific Affairs
- Pharmacovigilance
- Research
- Regulatory
- Business Development
- Marketing
Speaker Board
Patricio González Huerta
Asociación Mexicana de Lucha Contra el Cáncer, Mexico
Patient Coordinator
Patient Coordinator
María Eugenia Vargas Camaño
Instituto de Seguridad Social y Servicios de los Trabajadores del Estado (ISSSTE), Mexico
Clinical immunology and allergies Manager
Clinical immunology and allergies Manager
Mireya Lopez Gamboa
Pharma Research Organization & Centro Institucional de Farmacovigilancia del Instituto Nacional de Cancerología, Mexico
Director & Responsible
Director & Responsible
Helgi Jung
UNAM, Mexico
Head of the Department of Biopharmacy
Head of the Department of Biopharmacy
Francisco Cuauhtémoc Perdomo
Springfield Biotech, Mexico
Analytical Scientist Manager
Analytical Scientist Manager
Guillermo Caletti
Boehringer Ingelheim, Mexico
Head of Clinical Operations
Head of Clinical Operations
Lorenza Haddad
Codigo46, Mexico
CEO
CEO
Carlos Solis
Neolpharma, Mexico
Director of Biotechnology Unit
Director of Biotechnology Unit
Alison Bascou
BD, France
Sr. Regulatory Director
Sr. Regulatory Director
Vanda Magalhães, R&D Manager at Bionovis, Brazil
Bionovis, Brazil
R&D Manager
R&D Manager
Mauricio Rubio
Suanfarma, Colombia
Country Manager Colombia
Country Manager Colombia
Adilson Montaneira
Former Pfizer, Brazil
Business Unit Director - Biosimilar
Business Unit Director - Biosimilar
Renato Porto
ANVISA, Brazil
Director of Regulations
Director of Regulations
Marielle Pascual Quintero
Independent Consultant, Mexico
Expert in Regulatory Matters and Associate Professor
Expert in Regulatory Matters and Associate Professor
Francisco Kuri Breña
AMELAF, Mexico
Biotechnology Coordinator
Biotechnology Coordinator
Juan Gayosso
Sartorius, Mexico
Business Development Manager Biosimilars
Business Development Manager Biosimilars
Jaime Uribe
IGBA, Mexico
Member of Biosimilars Committee
Member of Biosimilars Committee
Fernando Fon
AMIIF, Mexico
Director Medical and Regulatory Affairs
Director Medical and Regulatory Affairs
The Influence of the 257 Mexican Standard into the Biologic’s Market
Panel Discussion: Interchangeability Real Scenario
Biosimilars, The Mexican Industry Approach
With the new government and in order to achieve universal coverage, Mexico must focus on local production of Biotechnology Drugs, increasing its National Integration percentage and implement consolidated purchases for the health system